The study, conducted by scientists at the University of Oklahoma, revealed that FGF21 operates through a region of the brain known as the hindbrain, a surprising finding since most researchers expected signals to come from another area called the hypothalamus.
The hindbrain is the same part of the brain targeted by some existing weight‑loss medications like GLP‑1 drugs, but FGF21 works in a completely different way.
Instead of suppressing hunger, FGF21 triggers parts of the hindbrain called the nucleus of the solitary tract (NTS) and the area postrema (AP). These regions then communicate with another brain structure known as the parabrachial nucleus.
This pathway appears to increase metabolic activity meaning the body burns more energy which leads to weight loss.
According to lead researcher Matthew Potthoff, Ph.D., understanding this brain circuit is important because it might help scientists design new weight‑loss therapies that are more effective and have fewer side effects than current options.
While some experimental FGF21‑based drugs are already being tested for a serious liver condition called MASH (metabolic dysfunction‑associated steatohepatitis), this research focuses specifically on how the hormone affects weight and metabolism.
One of the reasons this discovery is so promising is that FGF21 and existing medications target similar brain areas but produce different outcomes. GLP‑1 drugs like Ozempic and Wegovy reduce appetite, which helps people eat less.
FGF21, on the other hand, appears to increase the body’s natural ability to burn fat and use energy more efficiently, which could lead to powerful new ways to treat obesity.
Although these results are still early and have been observed in mice, the findings offer scientists a valuable new perspective on how the brain controls metabolism and body weight.
If future research confirms similar effects in humans, FGF21‑based therapies could eventually become a part of treatments for obesity and related conditions such as fatty liver disease.
Leave a Reply